VectorY's AAV-delivered antibody fragment VTx-001 demonstrated ability to neutralize oxidized phosphatidylcholines (PC-OxPL), which are implicated in triggering TDP-43 pathology and motor neuron degeneration in ALS.
Ventyx Biosciences initiated a Phase 2 trial of VTX3232 for obesity and cardiometabolic risk factors, with topline data expected in the second half of 2025.